JP7767290B2 - 新規なマスクされたサイトカインおよびその使用方法 - Google Patents
新規なマスクされたサイトカインおよびその使用方法Info
- Publication number
- JP7767290B2 JP7767290B2 JP2022542224A JP2022542224A JP7767290B2 JP 7767290 B2 JP7767290 B2 JP 7767290B2 JP 2022542224 A JP2022542224 A JP 2022542224A JP 2022542224 A JP2022542224 A JP 2022542224A JP 7767290 B2 JP7767290 B2 JP 7767290B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- cytokine
- moiety
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2033—IL-5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/206—IL-9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025182285A JP2026012891A (ja) | 2020-01-11 | 2025-10-29 | 新規なマスクされたサイトカインおよびその使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959973P | 2020-01-11 | 2020-01-11 | |
| US62/959,973 | 2020-01-11 | ||
| US202063027138P | 2020-05-19 | 2020-05-19 | |
| US63/027,138 | 2020-05-19 | ||
| US202063029473P | 2020-05-23 | 2020-05-23 | |
| US63/029,473 | 2020-05-23 | ||
| US202063126393P | 2020-12-16 | 2020-12-16 | |
| US63/126,393 | 2020-12-16 | ||
| PCT/US2021/013007 WO2021142471A1 (en) | 2020-01-11 | 2021-01-11 | Novel masked cytokines and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182285A Division JP2026012891A (ja) | 2020-01-11 | 2025-10-29 | 新規なマスクされたサイトカインおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509969A JP2023509969A (ja) | 2023-03-10 |
| JP2023509969A5 JP2023509969A5 (cg-RX-API-DMAC7.html) | 2023-09-06 |
| JP7767290B2 true JP7767290B2 (ja) | 2025-11-11 |
Family
ID=74562011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542224A Active JP7767290B2 (ja) | 2020-01-11 | 2021-01-11 | 新規なマスクされたサイトカインおよびその使用方法 |
| JP2025182285A Pending JP2026012891A (ja) | 2020-01-11 | 2025-10-29 | 新規なマスクされたサイトカインおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025182285A Pending JP2026012891A (ja) | 2020-01-11 | 2025-10-29 | 新規なマスクされたサイトカインおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12600762B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087864A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7767290B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN114901679B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205981A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165927A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142471A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| KR20260089650A (ko) * | 2019-07-12 | 2026-06-15 | 프로비바 테라퓨틱스 (홍콩) 리미티드 | Il-2 조성물 및 이의 사용 방법 |
| EP4013775A1 (en) * | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| WO2021062406A1 (en) * | 2019-09-28 | 2021-04-01 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| EP4284819A1 (en) * | 2021-02-01 | 2023-12-06 | Askgene Pharma, Inc. | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide |
| IL304916A (en) * | 2021-02-05 | 2023-10-01 | Salubris Biotherapeutics Inc | Il-15 fusion proteins and methods of making and using same |
| US20240390506A1 (en) * | 2021-09-28 | 2024-11-28 | Suzhou Fuse Biosciences Limited | Immunoconjugates containing tnf-alpha and related methods and compositions thereof |
| EP4435011A4 (en) * | 2021-11-15 | 2025-07-16 | Inst Biophysics Cas | FUSION PROTEIN CONSTRUCTION TAKING INTERLEUKIN 15 AS ACTIVE INGREDIENT AND USE THEREOF |
| CN116496408A (zh) * | 2022-01-21 | 2023-07-28 | 广东菲鹏制药股份有限公司 | 白细胞介素21及其受体复合物 |
| US12297247B2 (en) * | 2022-01-22 | 2025-05-13 | Nantcell, Inc. | Fusion molecules of CTLA4 and IL-15 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| WO2024039973A2 (en) * | 2022-08-05 | 2024-02-22 | Staidson Biopharma Inc. | Masking polypeptide, activatable novel prodrugs and methods of use thereof |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240327484A1 (en) * | 2023-03-31 | 2024-10-03 | Immunitybio, Inc. | Il-12/il-18 superkines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| IL326617A (en) * | 2023-08-30 | 2026-04-01 | Xilio Dev Inc | Masked il-2 cytokines and methods of use thereof |
| EP4784610A2 (en) * | 2023-09-26 | 2026-08-05 | Werewolf Therapeutics, Inc. | Activatable il-21 polypeptides and methods of use thereof and single domain human serum albumin antibodies |
| AU2024402334A1 (en) * | 2023-12-22 | 2026-05-28 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| TW202602921A (zh) * | 2024-02-09 | 2026-01-16 | 大陸商上海岸邁生物科技有限公司 | 多功能nk細胞接合器 |
| WO2026003219A1 (en) * | 2024-06-26 | 2026-01-02 | Anaveon AG | Proximity activated interleukin 21 |
| EP4671273A1 (en) * | 2024-06-26 | 2025-12-31 | Anaveon AG | INTERLEUKIN 21 PROXIMITY ACTIVATED |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026158432A1 (zh) * | 2025-01-24 | 2026-07-30 | 江苏奥赛康生物医药有限公司 | 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246392A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| GB0100551D0 (en) | 2001-01-09 | 2001-02-21 | Queen Mary & Westfield College | Protein |
| CA2456470A1 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| KR100911951B1 (ko) | 2001-08-23 | 2009-08-13 | 젠맵 에이/에스 | 인터루킨 15 (il-15)에 대하여 특이적인 인간 항체 |
| NZ567242A (en) | 2001-10-04 | 2009-11-27 | Genetics Inst Llc | Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer |
| EP3254687A1 (en) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| KR20050049545A (ko) | 2002-10-14 | 2005-05-25 | 에프. 호프만-라 로슈 아게 | 길항제 il-15 |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| CN1921879A (zh) | 2003-12-29 | 2007-02-28 | 明斯特大学临床医学院 | 由il-15刺激和活化毛发生长的方法 |
| CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| EP2109620B1 (en) | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CN102378768A (zh) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| WO2012061536A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CA2824515C (en) | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| US20150359853A1 (en) | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd8에의 항원 결합 구조체들 |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| EP3093295B1 (en) | 2014-01-08 | 2020-05-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterogeneous dimer protein and uses thereof |
| WO2015110930A1 (en) | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Modified interleukin 21 receptor proteins |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| AU2015244025B2 (en) | 2014-04-08 | 2019-03-21 | Boston Pharmaceuticals Inc. | Binding molecules specific for IL-21 and uses thereof |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| WO2016090173A1 (en) | 2014-12-03 | 2016-06-09 | Rxi Pharmaceuticals Corporation | Methods for the treatment of alopecia areata utilizing gene modulation approaches |
| US10905743B2 (en) | 2014-12-19 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016115275A1 (en) | 2015-01-13 | 2016-07-21 | City Of Hope | Ctla4-binding protein peptide-linker masks |
| WO2016112497A1 (zh) | 2015-01-13 | 2016-07-21 | 中国人民解放军军事医学科学院生物工程研究所 | 人源抗人α干扰素抗体及其应用 |
| US20160362469A1 (en) | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| GB201513033D0 (en) | 2015-07-23 | 2015-09-09 | Ucb Biopharma Sprl | Proteins |
| US10858452B2 (en) | 2015-09-16 | 2020-12-08 | Insitut National de la Sante et de la Recherche Medicale (INSERM) | Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| MX2018008416A (es) | 2016-01-08 | 2019-11-11 | Univ California | Polipéptidos heterodímericos condicionalmente activos y métodos para su uso. |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| WO2017162587A1 (en) | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US12202856B2 (en) | 2016-05-19 | 2025-01-21 | The General Hospital Corporation | Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| HRP20250482T1 (hr) | 2016-12-21 | 2025-06-20 | Cephalon Llc | Protutijela koja se specifično vežu na ljudski il-15 i njihove uporabe |
| CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| US11970537B2 (en) | 2017-12-26 | 2024-04-30 | Nanjing GenScript Biotech Co., Ltd. | Fusion protein dimer using antibody Fc region as backbone and use thereof |
| CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
| CA3115461A1 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| CA3087423A1 (en) | 2018-03-14 | 2019-09-19 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CN110174363A (zh) | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021021878A2 (pt) | 2019-05-03 | 2022-01-18 | Bioniz Llc | Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados |
| AU2020285636A1 (en) | 2019-05-24 | 2021-11-04 | Proviva Therapeutics (Hong Kong) Limited | IL-2 compositions and methods of use thereof |
| JP7778571B2 (ja) | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| EP4013775A1 (en) | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| EP4017594A1 (en) | 2019-08-21 | 2022-06-29 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| WO2021062406A1 (en) | 2019-09-28 | 2021-04-01 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| AU2021218927B2 (en) | 2020-02-10 | 2024-12-19 | Shanghai Escugen Biotechnology Co., Ltd. | Claudin 18.2 antibody and use thereof |
| WO2022032004A2 (en) | 2020-08-06 | 2022-02-10 | Abpro Corporation | Anti-claudin 18.2 multi-specific antibodies and uses thereof |
| US20250051413A1 (en) | 2021-01-12 | 2025-02-13 | Askgene Pharma Inc. | Chimeric molecules comprising il-12 agonist polypeptide |
| US20240076355A1 (en) | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| EP4284819A1 (en) | 2021-02-01 | 2023-12-06 | Askgene Pharma, Inc. | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide |
| WO2022178103A1 (en) | 2021-02-17 | 2022-08-25 | AskGene Pharma, Inc. | Il-2 receptor beta subunit mutants |
| WO2022221746A1 (en) | 2021-04-16 | 2022-10-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2024119193A2 (en) | 2022-12-02 | 2024-06-06 | AskGene Pharma, Inc. | Mutant il-2 polypeptides and il-2 prodrugs |
| CN119101162A (zh) | 2023-06-07 | 2024-12-10 | 江苏奥赛康生物医药有限公司 | 一种抗cldn18_2的抗体及体外诊断试剂盒 |
| WO2025122660A1 (en) | 2023-12-04 | 2025-06-12 | AskGene Pharma, Inc. | Chimeric proteins comprising masked il-2 |
-
2021
- 2021-01-11 AU AU2021205981A patent/AU2021205981A1/en active Pending
- 2021-01-11 JP JP2022542224A patent/JP7767290B2/ja active Active
- 2021-01-11 CN CN202180007592.8A patent/CN114901679B/zh active Active
- 2021-01-11 US US17/787,741 patent/US12600762B2/en active Active
- 2021-01-11 CN CN202411535046.3A patent/CN119386199A/zh active Pending
- 2021-01-11 WO PCT/US2021/013007 patent/WO2021142471A1/en not_active Ceased
- 2021-01-11 CA CA3165927A patent/CA3165927A1/en active Pending
- 2021-01-11 EP EP21704068.2A patent/EP4087864A1/en active Pending
- 2021-01-11 CN CN202411535037.4A patent/CN119367553A/zh active Pending
-
2025
- 2025-10-29 JP JP2025182285A patent/JP2026012891A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246392A1 (en) | 2018-06-22 | 2019-12-26 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4087864A1 (en) | 2022-11-16 |
| CN119386199A (zh) | 2025-02-07 |
| JP2023509969A (ja) | 2023-03-10 |
| JP2026012891A (ja) | 2026-01-27 |
| US20230108562A1 (en) | 2023-04-06 |
| CN114901679A (zh) | 2022-08-12 |
| AU2021205981A1 (en) | 2022-07-14 |
| CA3165927A1 (en) | 2021-07-15 |
| CN119367553A (zh) | 2025-01-28 |
| CN114901679B (zh) | 2025-03-11 |
| WO2021142471A1 (en) | 2021-07-15 |
| US12600762B2 (en) | 2026-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026012891A (ja) | 新規なマスクされたサイトカインおよびその使用方法 | |
| JP7820448B2 (ja) | 新規のサイトカインプロドラッグ | |
| KR102962557B1 (ko) | 새로운 il-15 프로드럭 및 이를 사용하는 방법 | |
| CN114401997B (zh) | 细胞因子前药和双前药 | |
| JP2024081657A (ja) | 新規il-21プロドラッグおよびそれを使用する方法 | |
| JP2022545439A (ja) | 新規il-21プロドラッグおよびその使用方法 | |
| US20250051413A1 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
| CN110461871A (zh) | 白蛋白结合结构域融合蛋白 | |
| TW202444743A (zh) | 干擾素α受體的變異體、包括其之融合蛋白及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250630 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250930 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7767290 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |